Gene · 23532
Papers1,874
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,874
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Diagnostic utility of PRAME immunohistochemistry for distinguishing clear cell sarcoma from malignant melanoma]. | Zhonghua Bing Li Xue Za Zhi | 2026 | 42252215 | PubTator, text mining | PubMed |
| Class 2 PRAME-Positive Ciliochoroidal Melanoma Metastasis to Fellow Eye. | Ophthalmol Retina | 2026 | 42249863 | PubTator, text mining | PubMed |
| Blue nevus-like melanoma: A rare entity. | Dermatol Online J | 2026 | 42246358 | PubTator, text mining | PubMed |
| A generalizable system for antigenic peptide targeting across HLA-I allotypes. | bioRxiv | 2026 | 42239416 | PubTator, text mining | PubMed |
| Expression of melanocytic markers in uterine smooth muscle tumours. | Histopathology | 2026 | 42186998 | PubTator, text mining | PubMed |
| The Landscape of Clinical Trials for TCR-T Cell Therapy. | Am J Clin Oncol | 2026 | 42184246 | PubTator, text mining | PubMed |
| Clinicopathologic characterization of primary anal canal mucosal melanomas: a single institution study. | Virchows Arch | 2026 | 42183907 | PubTator, text mining | PubMed |
| ACTIN::MITF-rearranged tumor: a distinctive entity or a cutaneous PEComa with MITF alterations? A clinicopathological and molecular study of additional 5 cases. | Virchows Arch | 2026 | 42171769 | PubTator, text mining | PubMed |
| DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling. | Transl Lung Cancer Res | 2026 | 42170260 | PubTator, text mining | PubMed |
| Giant dedifferentiated melanoma mimicking soft tissue sarcoma with loss of conventional melanocytic markers: diagnostic utility of PRAME and BRAF V600E immunohistochemistry. | Clin Exp Dermatol | 2026 | 42159209 | PubTator, text mining | PubMed |
| Transcriptomics and Mendelian randomization studies reveal the critical role of Stanniocalcin-2 in linking perfluorinated compound-exposure to colorectal cancer. | Front Public Health | 2026 | 42130894 | PubTator, text mining | PubMed |
| Prognostic value of PRAME gene promoter methylation and expression in hepatocellular carcinoma. | Clin Epigenetics | 2026 | 42104475 | PubTator, text mining | PubMed |
| Atypical Spitz Tumor With RET::MXT1 Gene Rearrangement in a 14-Year-Old Girl: An Integrated Histopathologic, Immunohistochemical, and Molecular Diagnostic Approach. | J Cutan Pathol | 2026 | 42095305 | PubTator, text mining | PubMed |
| Clinical utility of 23-gene expression profiling and concordance with PRAME immunohistochemistry in melanocytic neoplasms: A retrospective diagnostic accuracy study. | J Am Acad Dermatol | 2026 | 42067034 | PubTator, text mining | PubMed |
| A Primary Dedifferentiated Melanoma, Masquerading as a Soft Tissue Sarcoma, Displaying BRAF p.V600E, CDKN2A, TP53, and TERT Promoter Mutations. | Int J Surg Pathol | 2026 | 42024101 | PubTator, text mining | PubMed |
| Diagnostic Utility of PRAME and H3K27me3 in Distinguishing Malignant Melanoma From Proliferative Nodules on Congenital Melanocytic Nevi. | J Cutan Pathol | 2026 | 42017541 | PubTator, text mining | PubMed |
| CRTC1::TRIM11 Cutaneous Tumors With Atypia: Melanoma Mimicry, Aggressive Potential, and Methylation Classifier Limitations. | Genes Chromosomes Cancer | 2026 | 42015602 | PubTator, text mining | PubMed |
| A Novel PDZRN3::BRAF Fusion as Potential Driver Mechanism in BAP1-inactivated Melanocytoma. | Am J Dermatopathol | 2026 | 41996828 | PubTator, text mining | PubMed |
| A Novel Nanobody-Based TCR-like CAR T Therapy Targeting PRAME for the Treatment of Acute Myeloid Leukemia. | Clin Cancer Res | 2026 | 41985065 | PubTator, text mining | PubMed |
| Comment on: PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast. | Am J Clin Pathol | 2026 | 41969030 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23532/papers?page=3